Skip to content

Identification of Hit Inhibitors of SARS-CoV-2 NSP13 Helicase through Comprehensive Screening Cascade

Targeting NSP13 helicase, an enzyme critical for coronavirus replication and highly conserved across coronaviridae, presents both an opportunity and a challenge in antiviral discovery. This poster outlines a multidisciplinary strategy combining biochemical, biophysical, and fragment-based approaches to identify and characterize NSP13 inhibitors. The established assays, from NMR, ASMS and SPR to ATPase and unwinding assays, now support ongoing hit-to-lead optimization efforts.

Phenotypic Screen to Identify Inhibitors of Coronavirus Discontinuous Transcription

Coronaviruses rely on a unique process called discontinuous transcription to generate subgenomic RNAs essential for viral replication. This poster introduces a stable cell-based model of coronavirus replication, designed with a SARS-CoV replicon and NanoLuciferase reporter, enabling high-throughput screening for inhibitors of this process. Learn how phenotypic screening, supported by extensive follow-up assays, provides a framework for discovering potential pan-coronavirus antivirals.

Identification of SARS-CoV-2 Helicase Inhibitors Part 1

The search for broad-spectrum coronavirus antivirals remains urgent, as no drugs with cross-activity have yet been approved despite multiple outbreaks. In this first part of our work, we present the results of a high-throughput screening campaign against the viral helicase NSP13. Among the hit compounds identified, two series inhibit NSP13 by forming a covalent adduct with the protein. Although the series explored showed limited tractability, the findings demonstrate the feasibility of covalent approaches to this essential viral enzyme. This is Part 1 of the study—if you find it relevant, you may also be interested in downloading Part 2 for further insights.

Integrated Platforms for Rapid Identification of PROTACs and Covalent Fragments

Innovative strategies are reshaping small-molecule drug discovery, enabling access to previously “undruggable” targets. This poster presents IRBM’s integrated platforms for rapid hit identification, such as the Proteolysis Targeting Chimera (PROTAC) screening platform and the covalent fragment platform. The PROTAC platform leverages a "Direct to Biology" approach, pairing protein-of-interest ligands with a tailored ProtoDegron library for fast degrader evaluation, while the covalent fragment platform applies diverse electrophilic warhead-containing fragments to uncover starting points for covalent inhibitor design.

R2R01: A Potent Long-Acting RXFP1 Peptide Agonist in Phase 2 Development for Cardiovascular and Renal Disorders

R2R01 is a novel long-acting peptide agonist of RXFP1, developed as a potential therapy for cardiovascular and renal disorders. Building on the therapeutic promise of the natural hormone Relaxin-2, over 800 analogues were explored to overcome metabolic and safety limitations, resulting in potent single-chain agonists with enhanced stability and prolonged half-life. This poster outlines the discovery journey leading to R2R01, its distinctive pharmacological profile, and its advancement into Phase 2 clinical development.

From Chimeric Fragments to Functional Degraders: A Streamlined Platform for PROTAC Discovery

PROTACs represent a transformative strategy for degrading disease-relevant proteins, but their development is often resource-intensive and slow. This poster introduces an automated platform designed to accelerate the discovery of novel degraders by integrating direct-to-biology evaluation. With a dedicated ProtoDegron library and optimized workflows for rapid assembly and profiling, the approach offers a more efficient path toward expanding PROTAC discovery.

Identification of SARS-CoV-2 Helicase Inhibitors Part 2

NSP13 helicase is a critical component of coronavirus replication, yet notoriously difficult to target due to its conformational dynamics. In this second part, we share how IRBM’s covalent fragment platform was applied to this enzyme. This approach led to the identification and characterization of hits using a functional assay to monitor the enzymatic activity of the target protein, binding specificity was conducted by LC/MS analysis and peptide mapping allowed the identification of the cysteine residues binding sites. A preliminary SAR of one of the hit compounds enabled the optimization of activity and binding, open prospectives for future developability. This is Part 2 of the study—if interested, do not forget to download Part 1 for the full context.

One-Pot Solution-Phase Strategy for the Synthesis of Bicyclic Peptides Using the T3P/[Pd(PPh₃)₄] System

Macrolactam peptides are an emerging therapeutic modality suited to complex, traditionally undruggable targets, yet their synthesis remains difficult and often constrains their potential in drug discovery. This poster presents IRBM's streamlined strategy for bicyclic peptide production, developed to overcome the recurring obstacles of multistep synthesis while improving efficiency, reproducibility, and scalability. By simplifying a traditionally demanding route, the approach broadens practical access to conformationally constrained peptides for therapeutic development. Download the poster to explore how this strategy eases the main constraints of bicyclic peptide synthesis.

Generation and Biophysical Characterization of New α-Nsp13 Helicase mAbs, as a Powerful Tool for Studying SARS-CoV-2 Replication and Therapeutic Targeting

This poster presents the generation and biophysical characterization of novel rabbit-derived monoclonal antibodies against the SARS-CoV-2 NSP13 helicase, a highly conserved and essential component of the viral replication complex. These antibodies show high affinity and specificity, and have been validated in Western Blot and immunoassay formats. Their development addresses a critical gap in tools for studying helicase-targeting antivirals, enabling more precise investigation of NSP13 function and mechanism of action in cellular models.

Back To Top
No results found...